Theratechnologies Profit Margin 2011-2021 | THTX

Current and historical gross margin, operating margin and net profit margin for Theratechnologies (THTX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Theratechnologies net profit margin as of August 31, 2021 is -39%.
Theratechnologies Annual Profit Margins
Theratechnologies Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.290B $0.066B
Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.010B 7.90
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.357B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $6.783B 0.00
Arcus Biosciences (RCUS) United States $3.105B 0.00
Emergent Biosolutions (EBS) United States $2.254B 8.10
ADC Therapeutics SA (ADCT) Switzerland $1.478B 0.00
Myovant Sciences (MYOV) United Kingdom $1.368B 0.00
Zymeworks (ZYME) Canada $0.861B 0.00
Ambrx Biopharma (AMAM) United States $0.337B 0.00
SQZ Biotechnologies (SQZ) United States $0.319B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.90